entertainment -WSS

entertainment

author：Wikipedia 2025-09-28 02:29:54 - browse：8574

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Clinical trials giant ICON acquires HumanFirst

WSS

Obesity now affects over 1 billion people worldwide, study finds

Study identifies new proteins linked to dementia risk 25 years later

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Why Congress must ban federal programs from using QALYs

Hospitals struggle to profit from CAR

hotspot

entertainment

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Dobbs anniversary: the lost opportunity of abortion as health care

Clinical trials giant ICON acquires HumanFirst

Tori Bowie and the unacceptable rates of Black maternal death

Tocagen's brain cancer gene therapy trial continues. Investors worry

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

7 more heat

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

In search for therapies for solid tumors, companies turn to claudin

hotspot

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Driven by the pandemic, applicants flood public health schools

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Stanford president faces new allegations over 1999 paper

Tesla recalling nearly 16,000 of its 2021

An inside look at PIPEs, biotech's buzzy new financing tool

hotspot

hotspot

leisure time

entertainment